Ormutivimab Injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- North China Pharmaceutical Group New Drug Research and Development
- Medicine type
- Biologic
- Therapeutic area
- Infectious diseases
- Indications recorded in the public source
- Passive immunization after rabies virus exposure in adults and children aged 2 years and older. For category III exposures and exposures managed as category III; it must be used with rabies vaccine.
- Indication source and scope
- Source date(s): 2024-05-13. Manufacturer prescribing information for Mainland China.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Not matched in the 2025 national list; manual review pending
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance verification notes
- No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.
Sources
- https://cmei.org.cn/uploads/20220208/bcd9bbddedc7e52dbc33dbacedf8e169.pdf
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.shgpo.com/member/readflie.jspx?filePath=/u/cms/www/20250619/06162635i58y.pdf
Open the interactive record, public price references and discussions